January 26, 2024
Prognostic Significance of 8-Hydroxy-Deoxyguanosine Serum Levels in Irradiated Non-Small Cell Lung Cancer
Serum levels of 8-hydroxy-deoxyguanosine were positively correlated with ionizing radiation in non-small cell lung cancer, with possible prognostic significance in the squamous pathology subgroup in an observational study. Ionizing radiation is associated with DNA damage, which can be direct or indirect, as with the production of reactive oxygen species (ROS). The most common ROS-induced base...
Long Non-Coding RNA LINC02159 in Non-Small Cell Lung Cancer Progression
The long non-coding RNA LINC02159 promotes non-small cell lung cancer progression through ALYREF/YAP1 signaling, according to the results of a recent cell culture study. Lung cancer is the leading cause of cancer-related deaths globally. Long non-coding RNAs (lncRNAs) have recently emerged as key regulators in cancer development and progression, including non-small cell lung cancer (NSCLC),...
Amivantamab Plus Lazertinib for Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer
Amivantamab plus lazertinib shows durable clinical activity in osimertinib-relapsed, epidermal growth factor receptor-mutated advanced non-small cell lung cancer in a phase I study. Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), is the current standard-of-care treatment for EGFR-mutated non-small cell lung cancer (NSCLC). However, resistance is common, and there are no...
Circulating Tumor DNA Response to Pembrolizumab in Non-Small Cell Lung Cancer
Circulating tumor DNA response to pembrolizumab can identify patients with molecular disease progression needing treatment intensification, according to the results of a phase II/III clinical trial. Circulating tumor DNA (ctDNA) has demonstrated promise in identifying primary resistance to immunotherapy. Concerning non-small cell lung cancer (NSCLC), where pembrolizumab and combination pembrolizumab–carboplatin–taxane/pemetrexed are the first-line options, it...
Recent Advancements in Non-Small Cell Lung Cancer Treatment
A recent literature review identifies promising therapeutic agents that have shifted the non-small cell lung cancer treatment paradigm. Lung cancer is the leading cause of cancer mortality worldwide. Research is rapidly evolving regarding the treatment of non-small cell lung cancer (NSCLC) with biomarker-driven targeted therapy and immunotherapy using checkpoint inhibitors. A review of phase III...